60 related articles for article (PubMed ID: 20878578)
1. [Significance of plasmic L-plastin levels in the diagnosis of colorectal cancer].
Yuan CB; Zhao R; Wan FJ; Cai JH; Ji XP; Yu YY
Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Sep; 13(9):687-90. PubMed ID: 20878578
[TBL] [Abstract][Full Text] [Related]
2. Expression and clinical significance of L-plastin in colorectal carcinoma.
Li J; Zhao R
J Gastrointest Surg; 2011 Nov; 15(11):1982-8. PubMed ID: 21922341
[TBL] [Abstract][Full Text] [Related]
3. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
[TBL] [Abstract][Full Text] [Related]
4. Plasma TIMP-1 in patients with colorectal adenomas: a prospective study.
Holten-Andersen MN; Fenger C; Nielsen HJ; Rasmussen AS; Christensen IJ; Brünner N; Kronborg O
Eur J Cancer; 2004 Sep; 40(14):2159-64. PubMed ID: 15341992
[TBL] [Abstract][Full Text] [Related]
5. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.
Birgisson H; Nielsen HJ; Christensen IJ; Glimelius B; Brünner N
Eur J Cancer; 2010 Dec; 46(18):3323-31. PubMed ID: 20619633
[TBL] [Abstract][Full Text] [Related]
6. Presence of villin, a tissue-specific cytoskeletal protein, in sera of patients and an initial clinical evaluation of its value for the diagnosis and follow-up of colorectal cancers.
Dudouet B; Jacob L; Beuzeboc P; Magdelenat H; Robine S; Chapuis Y; Christoforov B; Cremer GA; Pouillard P; Bonnichon P
Cancer Res; 1990 Jan; 50(2):438-43. PubMed ID: 2295083
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
Holten-Andersen MN; Murphy G; Nielsen HJ; Pedersen AN; Christensen IJ; Høyer-Hansen G; Brünner N; Stephens RW
Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
10. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
11. [Tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer: correlation with clinico-morphological factors].
Korotkova EA; Gershteĭn ES; Prorokov VV; Kushlinskiĭ NE
Vopr Onkol; 2009; 55(2):171-6. PubMed ID: 19514370
[TBL] [Abstract][Full Text] [Related]
12. L-arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer.
Graboń W; Mielczarek-Puta M; Chrzanowska A; Barańczyk-Kuźma A
Clin Biochem; 2009 Mar; 42(4-5):353-7. PubMed ID: 19101531
[TBL] [Abstract][Full Text] [Related]
13. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
[TBL] [Abstract][Full Text] [Related]
15. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.
Roessler M; Rollinger W; Palme S; Hagmann ML; Berndt P; Engel AM; Schneidinger B; Pfeffer M; Andres H; Karl J; Bodenmüller H; Rüschoff J; Henkel T; Rohr G; Rossol S; Rösch W; Langen H; Zolg W; Tacke M
Clin Cancer Res; 2005 Sep; 11(18):6550-7. PubMed ID: 16166432
[TBL] [Abstract][Full Text] [Related]
16. Macrophage migration inhibitory factor in cancer.
Yasasever V; Camlica H; Duranyildiz D; Oguz H; Tas F; Dalay N
Cancer Invest; 2007 Dec; 25(8):715-9. PubMed ID: 18058468
[TBL] [Abstract][Full Text] [Related]
17. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse.
Yie SM; Lou B; Ye SR; Cao M; He X; Li P; Hu K; Rao L; Wu SM; Xiao HB; Gao E
Ann Surg Oncol; 2008 Nov; 15(11):3073-82. PubMed ID: 18670822
[TBL] [Abstract][Full Text] [Related]
18. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas.
Lee H; Rhee H; Kang HJ; Kim HS; Min BS; Kim NK; Kim H
Am J Clin Pathol; 2008 May; 129(5):772-9. PubMed ID: 18426738
[TBL] [Abstract][Full Text] [Related]
20. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ
Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
